⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplemental Figure 8 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth

Hilary A. Kenny Carman Ka Man Ip Lucy Kelliher Tejas Samantaray Kasjusz Kordylewicz Rachael Hoffmann Sarah Rauch Beatrice Malacrida Sophie L.P. Skingsley Frances R. Balkwill Chiara Battistini Ugo Cavallaro Wolf R. Wiedemeyer Ernst Lengyel

View at Publisher

Ask AI

Bookmark

Share

Key Points

Combination therapy using navitoclax and ym155 with carboplatin shows significant inhibition of ovarian cancer tumor growth.
The confirmatory dose-response screen reveals effective outcomes from the combined use of these inhibitors.
Methods involved measuring drug response curves to assess efficacy in reducing tumor size.
These findings support developing new treatment options that might improve outcomes for ovarian cancer patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Experimental findings demonstrate that navitoclax and YM155 enhance tumor inhibition in ovarian cancer, suggesting a potential combinatorial therapy.

Abstract

Drug response curves of the confirmatory screen dose-response screen

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kenny et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d02df https://doi.org/10.1158/1535-7163.29759659

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 5 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
2Supplemental Figure 10 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
3Supplemental Figure 9 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
4Supplemental Figure 2 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
5Supplemental Figure 11 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025

More related papers

Supplemental Figure 1 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
Supplemental Figure 4 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
Supplemental Figure 14 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025